PYXS · CIK 0001782223
Pyxis Oncology, Inc.
What Pyxis Oncology, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Pyxis Oncology, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 56stated 2026
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Pyxis Oncology, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2026. The description was written for this site in August 2026 from Pyxis Oncology, Inc. Form 10-K for fiscal year 2025, Pyxis Oncology, Inc. Form 10-Q for the quarter ended 30 June 2026, Pyxis Oncology, Inc. Form 8-K dated 13 August 2026, Exhibit 99.1 (second quarter 2026 results) and Pyxis Oncology, Inc. Form 8-K dated 2 July 2026 (private placement), not taken from any single article.
Share price
PYXS
Description
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company in Boston, Massachusetts that develops antibody drug conjugates for difficult-to-treat cancers. Its one active candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is a fully human IgG1 antibody joined by a cleavable linker to an auristatin payload, built on the FACT platform licensed from Pfizer. Unusually for an ADC, MICVO binds extradomain-B of fibronectin in the tumor extracellular matrix, killing cells by direct cytotoxicity, bystander effect and immunogenic cell death. It won FDA Fast Track designation in February 2025 in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO is in the Phase 1 PYX-201-101 monotherapy study, whose second line and later dose expansion hit target enrollment in early 2026, and in the PYX-201-102 Phase 1/2 escalation with Merck's pembrolizumab, with updated data guided for the fall and fourth quarter of 2026. The earlier PYX-106 and PYX-107 programs were deprioritized or deferred in December 2024. Net loss was $79.6 million in 2025 and $48.6 million in the first half of 2026. Cash and marketable debt securities were $33.0 million at 30 June 2026: with about $50 million of upfront proceeds from a private placement closed on 2 July 2026, management guides runway into the second quarter of 2027, though the filings carry a going concern warning.
Who owns Pyxis Oncology, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 75 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
75 managers reported a position, together holding 27.6m shares, or 43.5% of the company. The 40 largest are listed. Percentages are of the 63.4m shares outstanding at 8 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 747324101, held by bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, jpmorgan, morgan-stanley, northern-trust, pfizer, pnc, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.